The two most-studied healing peptides in modern recovery research — different mechanisms, different timelines, and a well-documented synergy when stacked.
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Mechanism | Cytoprotective pentadecapeptide; upregulates VEGF, modulates nitric oxide and growth-hormone receptor expression in injured tissue. | Synthetic 17-amino-acid fragment of Thymosin Beta-4; binds G-actin, drives cell migration and angiogenesis. |
| Half-life | ~4 hours systemic; local tissue effects persist longer | Short serum half-life, but actin-binding produces a much longer functional duration |
| Typical research dose | 250–500 mcg subcutaneous, 1–2× daily near injury site | 2.0–2.5 mg subcutaneous, 2× weekly loading then weekly maintenance |
| Best research use case | Gut, tendon, ligament and joint injury models; local soft-tissue repair | Systemic recovery, muscle injury, large-area wounds, scar remodelling |
| Onset of observed effect | Often within 1–2 weeks of consistent dosing | Slower — typically 3–4 weeks before researchers report changes |
| Administration | Subcutaneous, intramuscular, or oral (gastric stability is unusual) | Subcutaneous or intramuscular only |
| Stack synergy | Pairs with TB-500 (angiogenic + cytoprotective combo) | Pairs with BPC-157; also studied with GHK-Cu for connective tissue |
BPC-157 (Body Protection Compound) is a synthetic pentadecapeptide derived from a partial sequence of a protein discovered in human gastric juice. The 15-amino-acid sequence (GEPPPGKPADDAGLV) is unique in peptide research for its unusual oral stability — most peptides are degraded in the stomach, but BPC-157 was identified precisely because its parent protein survives there. TB-500 is a synthetic 17-amino-acid fragment of Thymosin Beta-4, a naturally occurring 43-amino-acid protein abundant in platelets and present in nearly every cell of the body. Where BPC-157 is novel, TB-500 reproduces a functional domain of a protein that is already a primary driver of human wound healing.
BPC-157 acts as a broad-spectrum cytoprotective agent. Animal studies have documented upregulation of VEGF (driving new blood vessel formation), modulation of the nitric oxide system, increased expression of growth-hormone receptors at injury sites, and protection of gut mucosa against NSAID-, alcohol- and ulcer-induced damage. It accelerates tendon-to-bone healing in rat Achilles models and has demonstrated activity in nerve regeneration. TB-500 operates through a much narrower but powerful pathway: its actin-binding domain sequesters G-actin and drives directed cell migration into damaged tissue, kicking off angiogenesis, fibroblast recruitment and re-epithelialisation. The two peptides hit overlapping endpoints — more blood vessels, faster cell migration — through different upstream mechanisms, which is the entire pharmacological argument for stacking them.
The pattern in published animal work and field reports is reasonably consistent. BPC-157 is the default for gut, tendon, ligament and small-area soft-tissue work, partly because its short half-life suits frequent local administration close to the injury site, and partly because of its near-unique oral bioavailability. TB-500 is reached for in larger systemic recovery situations — muscle tears, widespread tissue damage, scar remodelling — where its longer functional duration and systemic distribution matter more than precise local dosing. Onset timelines differ accordingly: researchers typically note BPC-157 effects within one to two weeks, while TB-500 results commonly take three to four weeks of consistent dosing before becoming evident.
The BPC-157 / TB-500 stack is one of the most widely documented combinations in equine veterinary literature, where both peptides are used extensively in racing recovery. The logical case is straightforward — BPC-157 provides cytoprotection, angiogenesis and local growth-factor expression while TB-500 drives the cell migration needed to actually populate the new vasculature with repairing tissue. The two have different time courses, so combining them produces both a fast cytoprotective response and a sustained remodelling phase. South African researchers studying either compound should source HPLC-tested material with a verifiable Certificate of Analysis; neither peptide is SAHPRA-approved for human use and both remain strictly research compounds.
BPC-157 Dosage Guide →
Dose tables by goal, local vs systemic injection and the BPC-157 + TB-500 stack protocol.
Healing Peptides South Africa →
Category overview of peptides studied for tissue repair and recovery.
Storage & Reconstitution Guide →
Correct storage temperatures and step-by-step BAC water reconstitution.
Peptides are an unscheduled grey area under SAHPRA — they are not approved for human use and are sold strictly for research purposes. Always source HPLC-tested material with a verifiable Certificate of Analysis, store correctly (lyophilised in the fridge or freezer; reconstituted in the fridge for up to 30 days), and review baseline bloodwork before beginning any research protocol.
Research Disclaimer: Information provided for educational and research purposes only. Not FDA or SAHPRA approved for human use. Consult a qualified healthcare provider before starting any protocol.